These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21677333)

  • 41. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
    McLaughlin K; Wajstaub S; Marotta P; Adams P; Grant DR; Wall WJ; Jevnikar AM; Rizkalla KS
    Liver Transpl; 2000 Sep; 6(5):570-4. PubMed ID: 10980055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.
    Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B
    J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
    Filipec-Kanizaj T; Budimir J; Colić-Cvrlje V; Kardum-Skelin I; Sustercić D; Naumovski-Mihalić S; Mrzljak A; Kolonić SO; Sobocan N; Bradić T; Dolić ZM; Kocman B; Katicić M; Zidovec-Lepej S; Vince A
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():37-43. PubMed ID: 23126028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
    Kim JM; Lee SK; Kim SJ; Joh JW; Kwon CH; Choe YH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS
    Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heart allograft involvement by posttransplant lymphoproliferative disorders: report from the PTLD. Int survey.
    Khedmat H; Taheri S
    Exp Clin Transplant; 2011 Aug; 9(4):258-64. PubMed ID: 21819371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of lymphoproliferative disease after liver transplantation.
    Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Posttransplant lymphoproliferative disorders in transplant recipients.
    Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
    Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
    Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An approach to finding indications and contraindications for nephrectomy in post-transplant renal graft lymphomas: PTLD.Int survey.
    Gholipour-Shoiili A; Gholipour-Shoiili H; Taheri S
    Hematol Oncol Stem Cell Ther; 2011; 4(4):167-72. PubMed ID: 22198192
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
    Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
    Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease.
    Mañez R; Breinig MC; Linden P; Wilson J; Torre-Cisneros J; Kusne S; Dummer S; Ho M
    J Infect Dis; 1997 Dec; 176(6):1462-7. PubMed ID: 9395355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Posttransplantation lymphoproliferative disorder in pediatric liver transplantation.
    Heo JS; Park JW; Lee KW; Lee SK; Joh JW; Kim SJ; Lee HH; Lee DS; Choi SH; Seo JM; Choe YH
    Transplant Proc; 2004 Oct; 36(8):2307-8. PubMed ID: 15561231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota.
    Wudhikarn K; Holman CJ; Linan M; Blaes AH; Dunitz JM; Hertz ME; Peterson BA
    Clin Transplant; 2011; 25(5):705-13. PubMed ID: 21077949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD20 antigen expression by lymphoma cells in lung allograft recipients is associated with higher remission rate and superior survival: a study on heart and lung transplant recipients.
    Gholipour-Shoiili A; Gholipour-Shoiili H; Taheri S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):29-37. PubMed ID: 24434379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.